A cooperative agreement has been announced by Illumina and Novogene on 15th of this month to jointly develop the Next Generation of Sequencing platform for applying to reproduction and tumor which means it become the other cooperation for Illumina to enlarging Chinese NGS technology market.

As the leader of global DNA sequencing and bio chips technology, Illumina held hands respectively with BerryGenomics and Anoroda in last May and June in the year, the first mentioned aimed to launch a high throughput sequencing solution based on Chinese market, the latter will associate with the high throughput sequencing platform utilizing in reproductive health.

Actually, the cooperation between BerryGenomics and Illumina has achievement at the beginning of the year, a genetic sequencing instrument (NextSeq CN500) and the testing reagent kits for Fetal Chromosome aneuploid (T13/T18/T21) have approved by CFDA.

Additionally, the 3 enterprises are outstanding in genomic sequencing field, also their founders were born from BGI (jokingly called “small BGI”). Illumina keeps stable its position in Chinese market through “small BGI”, and “small BGI” leveraging Illumina to compete with BGI.